|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0023434,
umls-concept:C0030705,
umls-concept:C0030956,
umls-concept:C0042196,
umls-concept:C0085358,
umls-concept:C0871261,
umls-concept:C1332717,
umls-concept:C1413244,
umls-concept:C1511636,
umls-concept:C1704632,
umls-concept:C1706438,
umls-concept:C1706817,
umls-concept:C2698600,
umls-concept:C2911692
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-4-14
|
|
pubmed:abstractText |
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic lymphocytic leukemia (CLL). CD8(+) T cells primed with the RHAMM-derived epitope R3, which is restricted by human leukocyte antigen (HLA)-A2, effectively lyse RHAMM(+) CLL cells. Therefore, we initiated a phase I clinical trial of R3 peptide vaccination. Six HLA-A2(+) CLL patients were vaccinated four times at biweekly intervals with the R3 peptide (ILSLELMKL; 300 microg per dose) emulsified in incomplete Freund's adjuvant; granulocyte-macrophage colony stimulating factor (100 microg per dose) was administered concomitantly. Detailed immunological analyses were conducted throughout the course of peptide vaccination. No severe adverse events greater than CTC I degrees skin toxicity were observed. Four patients exhibited reduced white blood cell counts during vaccination. In five of six patients, R3-specific CD8(+) T cells were detected with the corresponding peptide/HLA-A2 tetrameric complex; these populations were verified functionally in four of five patients using enzyme-linked immunosorbent spot (ELISpot) assays. In patients with clinical responses, we found increased frequencies of R3-specific CD8(+) T cells that expressed high levels of CD107a and produced both interferon-gamma and granzyme B in response to antigen challenge. Interestingly, vaccination was also associated with the induction of regulatory T cells in four patients. Thus peptide vaccination in six CLL patients was safe and could elicit to some extent specific CD8(+) T-cell responses against the tumor antigen RHAMM.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1476-5551
|
|
pubmed:author |
pubmed-author:DöhnerHH,
pubmed-author:DmoszynskaAA,
pubmed-author:GiannopoulouMM,
pubmed-author:GostickEE,
pubmed-author:GreinerJJ,
pubmed-author:KowalMM,
pubmed-author:PriceD ADA,
pubmed-author:RojewskiMM,
pubmed-author:RolinskiJJ,
pubmed-author:SchmittMM,
pubmed-author:StilgenbauerSS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
798-805
|
|
pubmed:meshHeading |
pubmed-meshheading:20220777-Adult,
pubmed-meshheading:20220777-Aged,
pubmed-meshheading:20220777-Antigens, CD44,
pubmed-meshheading:20220777-CD8-Positive T-Lymphocytes,
pubmed-meshheading:20220777-Cancer Vaccines,
pubmed-meshheading:20220777-Cell Proliferation,
pubmed-meshheading:20220777-Epitopes, T-Lymphocyte,
pubmed-meshheading:20220777-Extracellular Matrix Proteins,
pubmed-meshheading:20220777-Feasibility Studies,
pubmed-meshheading:20220777-Female,
pubmed-meshheading:20220777-Flow Cytometry,
pubmed-meshheading:20220777-HLA-A2 Antigen,
pubmed-meshheading:20220777-Humans,
pubmed-meshheading:20220777-Immunotherapy,
pubmed-meshheading:20220777-Interferon-gamma,
pubmed-meshheading:20220777-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:20220777-Lymphocyte Count,
pubmed-meshheading:20220777-Male,
pubmed-meshheading:20220777-Middle Aged,
pubmed-meshheading:20220777-Peptide Fragments,
pubmed-meshheading:20220777-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:20220777-T-Lymphocytes, Regulatory,
pubmed-meshheading:20220777-Vaccination
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
|
|
pubmed:affiliation |
Clinical Immunology Department, Medical University of Lublin, Lublin, Poland. giannop@tlen.pl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
